RBC Capital Maintains Their Buy Rating on Caribou Biosciences (CRBU)

In a report issued on July 15, Luca Issi from RBC Capital maintained a Buy rating on Caribou Biosciences (CRBUResearch Report), with a price target of $22.00. The company’s shares closed last Monday at $6.73, close to its 52-week low of $4.89.

According to, Issi is ranked 0 out of 5 stars with an average return of -19.7% and a 27.5% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, BioMarin Pharmaceutical, and Adverum Biotechnologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Caribou Biosciences with a $26.25 average price target, which is a 262.1% upside from current levels. In a report issued on July 12, SVB Securities also reiterated a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Caribou Biosciences’ market cap is currently $434.7M and has a P/E ratio of -5.92.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBU in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

Read More on CRBU:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More